Genevant Sciences

Genevant Sciences company information, Employees & Contact Information

Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering
Looking for a particular Genevant Sciences employee's phone or email?

Genevant Sciences Questions

News

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Genevant Sciences and Arbutus Biopharma Initiate GlobeNewswire

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M - Fierce Biotech

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M Fierce Biotech

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - Stock Titan

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global Stock Titan

Arbutus, Genevant expand COVID patent feud with Moderna with 5 international lawsuits - Fierce Pharma

Arbutus, Genevant expand COVID patent feud with Moderna with 5 international lawsuits Fierce Pharma

Epitopea teams up with Genevant in $124 million deal - The Pharma Letter

Epitopea teams up with Genevant in $124 million deal The Pharma Letter

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics - Sarepta Therapeutics

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics Sarepta Therapeutics

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics - Yahoo Finance

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics Yahoo Finance

Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance - ACS Publications

Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance ACS Publications

Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid‐Nanoparticle Components for Therapeutic and Vaccine Applications - Lam - 2023 - Advanced Materials - Wiley Online Library

Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid‐Nanoparticle Components for Therapeutic and Vaccine Applications - Lam - 2023 - Advanced Materials Wiley Online Library

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency - Business Wire

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency Business Wire

Editas and Genevant team up to develop gene editing therapies - Pharmaceutical Technology

Editas and Genevant team up to develop gene editing therapies Pharmaceutical Technology

Foley Hoag Represents Genevant Sciences in Global Collaboration and License Agreement with Takeda - Foley Hoag

Foley Hoag Represents Genevant Sciences in Global Collaboration and License Agreement with Takeda Foley Hoag

Arbutus and Brinkhof celebrate interim success in mRNA case against Moderna - JUVE Patent

Arbutus and Brinkhof celebrate interim success in mRNA case against Moderna JUVE Patent

Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award - Yahoo Finance

Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award Yahoo Finance

Optimizing Lipid Nanoparticles for Delivery in Primates - Wiley

Optimizing Lipid Nanoparticles for Delivery in Primates Wiley

Genevant secures $114M deal with newly launched Tome to develop gene editing liver disorder therapy - Fierce Biotech

Genevant secures $114M deal with newly launched Tome to develop gene editing liver disorder therapy Fierce Biotech

Repair Biotechnologies and Genevant Sciences to Collaborate - GlobeNewswire

Repair Biotechnologies and Genevant Sciences to Collaborate GlobeNewswire

Gritstone goes back to Genevant to boost power of infectious disease vaccine programs - Fierce Biotech

Gritstone goes back to Genevant to boost power of infectious disease vaccine programs Fierce Biotech

Repair licenses Genevant's nucleic acid delivery tech for up to $107M per cardio product - Fierce Biotech

Repair licenses Genevant's nucleic acid delivery tech for up to $107M per cardio product Fierce Biotech

Partners will work to further gene-editing treatment for hemophilia A - Hemophilia News Today

Partners will work to further gene-editing treatment for hemophilia A Hemophilia News Today

2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing project - Fierce Pharma

2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing project Fierce Pharma

Arbutus, Genevant gain an edge in COVID patent scrap with Moderna - Fierce Pharma

Arbutus, Genevant gain an edge in COVID patent scrap with Moderna Fierce Pharma

COVID-19 patent fights continue as Arbutus, Genevant come after Pfizer and BioNTech in new lawsuit - Fierce Pharma

COVID-19 patent fights continue as Arbutus, Genevant come after Pfizer and BioNTech in new lawsuit Fierce Pharma

Genevant pens $303M biobucks pact with Takeda, aiming at rare liver diseases using gene therapy - Fierce Biotech

Genevant pens $303M biobucks pact with Takeda, aiming at rare liver diseases using gene therapy Fierce Biotech

Moderna Seeks Dismissal in US Court of COVID-19 Vaccine Patent Infringement Lawsuit By Arbutus, Genevant - Health Policy Watch

Moderna Seeks Dismissal in US Court of COVID-19 Vaccine Patent Infringement Lawsuit By Arbutus, Genevant Health Policy Watch

Genevant and Arbutus initiate patent lawsuit against Moderna - The Pharma Letter

Genevant and Arbutus initiate patent lawsuit against Moderna The Pharma Letter

Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space - JD Supra

Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space JD Supra

Takeda signs LNP deal with Genevant worth up to $600 million - Chemical & Engineering News

Takeda signs LNP deal with Genevant worth up to $600 million Chemical & Engineering News

After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech - Fierce Pharma

After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech Fierce Pharma

Genevant inks development deal with BioNTech - BioPharma Dive

Genevant inks development deal with BioNTech BioPharma Dive

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond Law360

Arbutus, Genevant Escape Acuitas Suit on Covid-Shot Tech Patents - Bloomberg Law News

Arbutus, Genevant Escape Acuitas Suit on Covid-Shot Tech Patents Bloomberg Law News

Judge Rules Against Moderna in COVID-19 Patent Fight with Roivant Subsidiary - BioSpace

Judge Rules Against Moderna in COVID-19 Patent Fight with Roivant Subsidiary BioSpace

Roche executive jumps ship to Ramaswamy’s Genevant, joining fellow former Big Pharma veteran - Fierce Biotech

Roche executive jumps ship to Ramaswamy’s Genevant, joining fellow former Big Pharma veteran Fierce Biotech

Arbutus and Genevant extend Moderna patent trial to 2025 - Investing.com

Arbutus and Genevant extend Moderna patent trial to 2025 Investing.com

Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant - Endpoints News

Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant Endpoints News

Moderna sued over Covid-19 vaccine-related patents - Chemistry World

Moderna sued over Covid-19 vaccine-related patents Chemistry World

Roivant, Arbutus set up RNA JV, put ex-Ariad, Roche executives in leadership posts - Fierce Biotech

Roivant, Arbutus set up RNA JV, put ex-Ariad, Roche executives in leadership posts Fierce Biotech

Pfizer Accused of Covid-19 Vaccine Patent Infringement Again, This Time by Arbutus and Genevant - StatNano

Pfizer Accused of Covid-19 Vaccine Patent Infringement Again, This Time by Arbutus and Genevant StatNano

Another Notch on the Belt as Ramaswamy Launches Genevant - BioSpace

Another Notch on the Belt as Ramaswamy Launches Genevant BioSpace

Life-sciences research facilities sprouting in Vancouver’s South Flatz - The Globe and Mail

Life-sciences research facilities sprouting in Vancouver’s South Flatz The Globe and Mail

Epitopea signs deal with Genevant Sciences worth $123.5m per product - Cambridge Independent

Epitopea signs deal with Genevant Sciences worth $123.5m per product Cambridge Independent

Gènavant spring/summer 2019 collection presentation for LFW - The Upcoming

Gènavant spring/summer 2019 collection presentation for LFW The Upcoming

Top Genevant Sciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant